

表3-20

Time Devoted to Monitoring Medication Therapy and Percentage of Patients Monitored by Pharmacists

項目	2006	2003 ³	2000 ²
薬物療法のモニターに 薬剤師の割いた時間 ^a			
<10%	14.1	18.2	21.0
10-19%	37.0	32.7	31.9
20-29%	25.1	28.4	24.2
>29%	23.7	20.8	23.0
薬剤師によってモニター されている患者数 ^b			
<26%	22.1	30.7	43.3
26-50%	34.2	26.5	19.3
51-75%	19.4	19.8	17.0
>75%	24.4	23.0	20.3

Pedersen et al., ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education — 2006, Am J Health-Syst Pharm, 64, 507-520, 2007

POSITION & GUIDANCE DOCUMENTS OF ASHP

BEST PRACTICES

for Hospital &
Health-System
Pharmacy

2008-2009 Edition

American Society of Health-System Pharmacists®
Bethesda, Maryland

The ASHP policies in this book, positions and guidance documents, are intended to foster improvements in pharmacy practice and patient care. The content of individual positions and guidance documents should be assessed in the context of your own health system, its policies and procedures, as well as applicable federal and state laws and regulations.

Guidance documents, in particular, evolve because of advances in technology, new knowledge from research, and lessons from experience. Additionally, medication information is constantly evolving because of ongoing research and clinical experience, and it is often subject to interpretation and unique clinical situations. The American Society of Health-System Pharmacists (ASHP) endeavors to ensure the completeness and timeliness of the information presented. However, the reader is advised that the publisher, contributors, editors, and reviewers make no representations concerning the suitability of the information for any purpose, and are not responsible for the immediate currency of the information, for any errors or omissions, or for any consequences arising from the use of these materials. All decisions made within the context of pharmacy practice should be based on the independent judgment of the practitioner.

For more than 60 years, ASHP has helped pharmacists who practice in hospitals and health systems improve medication use and enhance patient safety. The Society's 35,000 members include pharmacists and pharmacy technicians who practice in inpatient, outpatient, home-care, and long-term-care settings, as well as pharmacy students. For more information about the wide array of ASHP activities and the many ways in which pharmacists help people make the best use of medicines, visit ASHP's Web site, www.ashp.org, or its consumer Web site, www.SafeMedication.com.

Editor: Bruce Hawkins

Published by the American Society of Health-System Pharmacists, 7272 Wisconsin Avenue, Bethesda, MD 20814.

ASHP® is a service mark of the American Society of Health-System Pharmacists®, Inc.; registered in the U.S. Patent and Trademark Office.

© Copyright 2008, American Society of Health-System Pharmacists®, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval systems, without written permission from the American Society of Health-System Pharmacists®.

ISBN: 978-1-58528-220-3

Contents

Page Locator for Guidance Documents by Type and Title	xii
Acknowledgments	xiv
Introduction	xx
Mission Statement.....	xxiii
Vision Statement	xxiii
Automation and Information Technology	
POSITIONS:	
0712 - Electronic Health and Business Technology and Services	4
0507 - Electronic Information Systems.....	4
0523 - Online Pharmacy and Internet Prescribing	4
0203 - Pharmacist's Role in Electronic Patient Information and Prescribing Systems.....	4
0105 - Computerized Prescriber Order Entry.....	4
9919 - Management of Blood Products and Derivatives.....	4
9920 - Telepharmacy	4
9813 - Regulation of Automated Drug Distribution Systems	5
9205 - Automated Systems	5
STATEMENTS:	
*Bar-Code-Enabled Medication Administration Technology	6
Pharmacist's Role in Informatics	9
Pharmacist's Role with Respect to Drug Delivery Systems and Administration Devices	13
GUIDELINES:	
Safe Use of Automated Compounding Devices for the Preparation of Parenteral Nutrition Admixtures	15
Safe Use of Automated Medication Storage and Distribution Devices	20
Drug Distribution and Control	
POSITIONS:	
0611 - Redistribution of Unused Medications	26
0401 - Pharmaceutical Counterfeiting.....	26
0303 - Pharmacy Drug Theft.....	26
0232 - Pharmacist's Role in Drug Procurement, Distribution, Surveillance, and Control	26
9903 - Optimizing the Medication-Use Process.....	26
PROCUREMENT	
POSITION:	
0524 - Prudent Purchasing of Pharmaceuticals.....	27
GUIDELINES:	
Managing Drug Product Shortages	28
Selecting Pharmaceutical Manufacturers and Suppliers	33
PREPARATION AND HANDLING	
POSITIONS:	
0614 - Safe Disposal of Patients' Home Medications.....	35
0616 - Safe and Effective Extemporaneous Compounding.....	35
0617 - Accreditation of Compounding Facilities	35
0231 - Pharmaceutical Waste	35

GUIDELINES:	Handling Hazardous Drugs	36
	Pharmacy-Prepared Ophthalmic Products	56
	Quality Assurance for Pharmacy-Prepared Sterile Products.....	58
TAB:	Compounding Nonsterile Products in Pharmacies.....	77
DISTRIBUTION		
POSITIONS:	0522 - New and Emerging Medication Ordering and Distribution Systems.....	84
	0310 - Technician-Checking-Technician Programs	84
	0220 - Intermediate Category of Drugs	84
	0010 - Dispensing by Nonpharmacists and Nonprescribers	84
STATEMENTS:	Pharmacist's Responsibility for Distribution and Control of Drug Products	85
	Unit Dose Drug Distribution	86
TABS:	Hospital Drug Distribution and Control.....	87
	Repackaging Oral Solids and Liquids in Single Unit and Unit Dose Packages.....	96
	Single Unit and Unit Dose Packages of Drugs.....	98

Education and Training

POSITIONS:	*0802 - Role of Pharmacy Interns.....	102
	*0803 - Standardized Pharmacy Technician Training as a Prerequisite for Certification....	102
	*0804 - Collaboration Regarding Experiential Education	102
	*0805 - Entry-Level Doctor of Pharmacy Degree.....	102
	0701 - Requirement for Residency.....	102
	0702 - Pharmacy Technician Training.....	102
	0704 - Residency Programs.....	102
	0705 - ASHP Guidelines, Statements, and Professional Policies as an Integral Part of the Educational Process	102
	0607 - Quality of Pharmacy Education and Expansion of Colleges of Pharmacy	102
	0608 - Interdisciplinary Health Professions Education.....	102
	0509 - Developing Leadership and Management Competencies.....	102
	0510 - Communication Among Health-System Pharmacy Practitioners, Patients, and Other Health Care Providers.....	103
	0408 - Continuing Professional Development	103
	0313 - Patient-Centered Care	103
	0314 - Cultural Competence.....	103
	0315 - Practice Sites for Colleges of Pharmacy	103
	0323 - Licensure for Pharmacy Graduates of Foreign Schools.....	103
	0325 - Public Funding for Pharmacy Residency Training	103
	0209 - Substance Abuse and Chemical Dependency	104
	0217 - "P.D." (Pharmacy Doctor) Designation for Pharmacists.....	104
	0107 - Nonaccredited Pharm.D. Programs.....	104
	0108 - Nontraditional Pharm.D. Accessibility	104
	0005 - Residency Training for Pharmacists Who Provide Direct Patient Care.....	104

*Indicates content that has been added or revised since the 2007–2008 edition.

	9901 - Fostering Pharmacy Leadership.....	104
	9911 - Pharmacy Residency Training	104
	8507 - Career Counseling.....	104
<i>STATEMENT:</i>	Continuing Education	105
<i>ENDORSED:</i>	Definitions of Pharmacy Residencies and Fellowships.....	106

Ethics

<i>POSITIONS:</i>	0610 - Pharmacist’s Right of Conscience and Patient’s Right of Access to Therapy	110
	0517 - Ethical Use of Placebos.....	110
	0013 - Patient’s Right to Choose.....	110
	9915 - ASHP Position on Assisted Suicide.....	110
	9006 - Nondiscriminatory Pharmaceutical Care	110
	8410 - Use of Drugs in Capital Punishment.....	110
<i>STATEMENTS:</i>	Pharmacist’s Decision-making on Assisted Suicide	111
	Professionalism	114
<i>GUIDELINE:</i>	Pharmacists’ Relationships with Industry	117
<i>ENDORSED:</i>	Code of Ethics for Pharmacists	118

Formulary Management (Medication-Use Policy Development)

<i>POSITIONS:</i>	*0809 - Medications Derived from Biologic Sources.....	120
	*0817 - Generic Substitution of Narrow Therapeutic Index Drugs	120
	0305 - Expression of Therapeutic Purpose of Prescribing	120
	0228 - Appropriate Dosing of Medications in Patient Populations with Unique Needs	120
	0102 - Medication Formulary System Management.....	120
	0103 - Gene Therapy.....	120
	0016 - Pharmacogenomics	120
	9819 - Role of Pharmacists and Business Leaders in Health Care Services and Policies	120
	9601 - Standardization of Drug Medication Formulary Systems.....	120
	9106 - Medical Devices.....	121
	8708 - Therapeutic Interchange.....	121
<i>STATEMENTS:</i>	*Pharmacy and Therapeutics Committee and the Formulary System.....	122
	Use of Medications for Unlabeled Uses	125
<i>GUIDELINES:</i>	Medication-Use Evaluation	127
	*Pharmacy and Therapeutics Committee and the Formulary System.....	130
<i>ENDORSED:</i>	Principles of a Sound Drug Formulary System.....	140

Government, Law, and Regulation

<i>POSITIONS:</i>	*0811 - Regulation of Dietary Supplements	146
	*0813 - Medicare Prescription Drug Benefit	146
	*0814 - Federal Review of Anticompetitive Practices by Drug Product Manufacturers	146
	*0815 - Uniform State Laws and Regulations Regarding Pharmacy Technicians.....	146

*Indicates content that has been added or revised since the 2007–2008 edition.

	0716 - Regulation of Telepharmacy Services	146
	0719 - FDA Authority to Prohibit Reuse of Brand Names	147
	0722 - Pharmaceutical Product and Supply Chain Integrity	147
	0723 - Removal of Propoxyphene from the Market.....	147
	0602 - Minimum Effective Doses	147
	0612 - Streamlined Licensure Reciprocity.....	147
	0506 - Accessibility and Affordability of Pharmaceuticals	147
	0512 - Full Health Insurance Coverage.....	147
	0513 - Postmarketing Comparative Clinical Studies.....	147
	0514 - Premarketing Comparative Clinical Studies	147
	0515 - Postmarketing Safety Studies.....	147
	0516 - Mandatory Registry of Clinical Trials	148
	0518 - Funding, Expertise, and Oversight of State Boards of Pharmacy	148
	0519 - Approval of Generic Biologic Medications.....	148
	0411 - Compounding by Health Professionals.....	148
	0413 - Importation of Pharmaceuticals	148
	0319 - Drug Product Shortages	148
	0222 - Greater Access to Less Expensive Generic Drugs.....	148
	0012 - FDA's Public Health Mission.....	148
	9902 - Compliance with Governmental Payment Policies.....	149
	9010 - Generic Pharmaceutical Testing.....	149
STATEMENTS:	*Criteria for an Intermediate Category of Drug Products.....	150
	Over-the-Counter Availability of Statins.....	153
	Principles for Including Medications and Pharmaceutical Care in Health Care Systems.....	156
 Medication Misadventures		
POSITIONS:	0604 - Minimizing the Use of Abbreviations.....	158
	0227 - Pharmacist's Responsibility for Patient Safety	158
	0011 - Statutory Protection for Medication-Error Reporting.....	158
	0020 - Drug Names, Labeling, and Packaging Associated with Medication Errors.....	158
	0021 - Medication Errors and Risk Management	158
	9918 - Reporting Medication Errors and Adverse Drug Reactions	158
	9805 - Medication Misadventures.....	158
	9609 - Human Factors Concepts	158
STATEMENT:	Reporting Medical Errors.....	159
GUIDELINES:	Adverse Drug Reaction Monitoring and Reporting	160
	Preventing Medication Errors in Hospitals	163
	Preventing Medication Errors with Antineoplastic Agents.....	172
ENDORSED:	Recommendations from the National Coordinating Council for Medication Error Reporting and Prevention	189

Medication Therapy and Patient Care

ORGANIZATION AND DELIVERY OF SERVICES

<i>POSITIONS:</i>	*0806 - Health-System Use of Medications and Administration Devices Supplied Directly to Patients	194
	*0807 - Standardization of Intravenous Drug Concentrations	194
	*0816 - Pharmacist's Leadership Role in Anticoagulation Therapy Management	194
	0707 - Standard Drug Administration Schedules	194
	0601 - Universal Influenza Vaccination	194
	0619 - Integrated Team-Based Approach for the Pharmacy Enterprise	194
	0620 - Pharmacists' Role in Medication Reconciliation	194
	0502 - Health Care Quality Standards and Pharmacy Services	194
	0503 - Critical-Access, Small, and Rural Hospitals	195
	0505 - Health-System Facility Design	195
	0525 - Mandatory Tablet Splitting for Cost Containment	195
	0403 - Scope and Hours of Pharmacy Services	195
	0407 - Documentation of Pharmacist Patient Care Services	195
	0301 - Continuity of Care	195
	0202 - Performance Improvement	195
	0101 - Pharmacy Benefits for the Uninsured	195
	0104 - Patient Satisfaction	195
	0116 - Patient Adherence Programs as Part of Health Insurance Coverage	196
	9921 - Pharmacist Validation of Information Related to Medications	196
	9801 - Collaborative Drug Therapy Management Activities	196
	9804 - Multidisciplinary Action Plans for Patient Care	196
	9812 - Collaborative Drug Therapy Management	196
	9820 - Medication Administration by Pharmacists	196
<i>STATEMENTS:</i>	*Confidentiality of Patient Health Care Information	197
	*Hospitalist-Pharmacist Collaboration	198
	Pharmaceutical Care	202
<i>GUIDELINES:</i>	Documenting Pharmaceutical Care in Patient Medical Records	205
	Pharmacist-Conducted Patient Education and Counseling	208
	Pharmacist's Role in the Development, Implementation, and Assessment of Critical Pathways	211
	Standardized Method for Pharmaceutical Care	217

SPECIFIC PRACTICE AREAS

<i>POSITIONS:</i>	0710 - Role of Pharmacists in Sports Pharmacy and Doping Control	220
	0306 - Pain Management	220
	0307 - Pharmacist Support for Dying Patients	220
	0213 - Pharmacists' Role in Immunization and Vaccines	220

*Indicates content that has been added or revised since the 2007–2008 edition.

	9711 - Interventions to Reduce HIV Risk Behavior in Intravenous Drug Users	220
	9407 - Primary and Preventive Care.....	220
STATEMENTS:	Pharmacist's Role in Clinical Pharmacokinetic Monitoring	221
	Pharmacist's Role in Hospice and Palliative Care.....	223
	Pharmacist's Role in Infection Control	227
	Pharmacist's Role in Primary Care	229
	Pharmacist's Role in Substance Abuse Prevention, Education, and Assistance	232
	Pharmacist's Role in the Care of Patients with HIV Infection.....	236
	*Pharmacy Services to the Emergency Department	241
	Racial and Ethnic Disparities in Health Care.....	244
	Role of Health-System Pharmacists in Emergency Preparedness	249
	Role of Health-System Pharmacists in Public Health.....	251
	Use of Dietary Supplements.....	256
GUIDELINES:	Pharmacist's Role in Immunization	261
	Providing Pediatric Pharmaceutical Services in Organized Health Care Systems.....	267
	Provision of Medication Information by Pharmacists.....	270
	Surgery and Anesthesiology Pharmaceutical Services	273

Pharmaceutical Industry

DRUG PRODUCTS, LABELING, AND PACKAGING

POSITIONS:	*0801 - Alternative Drug Coding Systems	282
	*0808 - Disclosure of Excipients in Drug Products.....	282
	0715 - Patient Access to Orphan Drug Products.....	282
	0720 - Standardizing Prefixes and Suffixes in Drug Product Names	282
	0618 - Elimination of Surface Contamination on Vials of Hazardous Drugs	282
	0501 - Mandatory Labeling of the Presence of Latex.....	282
	0402 - Ready-to-Use Packaging for All Settings	282
	0404 - Standardization, Automation, and Expansion of Manufacturer-Sponsored Patient-Assistance Programs	282
	0309 - Unit Dose Packaging Availability	282
	0002 - Drug Shortages.....	282
	9707 - Pediatric Dosage Forms	283
	9608 - Use of Color to Identify Drug Products.....	283
	9309 - Expiration Dating of Pharmaceutical Products.....	283
	9211 - Tamper-Evident Packaging on Topical Products	283
	9011 - Drug Nomenclature.....	283
	8709 - Codes on Solid Dosage Forms of Prescription Drug Products	283
	8612 - International System of Units	283
	8613 - Elimination of Apothecary System.....	283
	8310 - Size, Color, and Shape of Drug Products.....	283

*Indicates content that has been added or revised since the 2007–2008 edition.

MARKETING

POSITIONS: 0714 - Restricted Drug Distribution 284
 0603 - Medication Management for Patient Assistance Programs 284
 0605 - Pharmaceutical Distribution Systems 284
 0609 - Direct-to-Consumer Advertising of Prescription and Nonprescription Medications 284
 9702 - Drug Samples 284
 9703 - Manufacturer-Sponsored Patient-Assistance Programs 284
GUIDELINE: Activities of Vendors’ Representatives in Organized Health Care Systems 285

Pharmacy Management

POSITIONS: 0606 - Pharmacist Leadership of the Pharmacy Department 288
 0504 - Pharmacy Staff Fatigue and Medication Errors 288
 0406 - Workload Monitoring and Reporting 288
STATEMENTS: *Roles and Responsibilities of the Pharmacy Executive 289
 *Standards-Based Pharmacy Practice in Hospitals and Health Systems 292
GUIDELINES: *Medication Cost Management Strategies for Hospitals and Health Systems 294
 Outsourcing Pharmaceutical Services 309

COMPENSATION AND REIMBURSEMENT

POSITIONS: 0708 - Pay-for-Performance Reimbursement 316
 0206 - Reimbursement for Unlabeled Uses of FDA-Approved Drug Products 316
 0207 - Product Reimbursement and Pharmacist Compensation 316

HUMAN RESOURCES

POSITIONS: *0810 - Education, Prevention, and Enforcement Concerning Workplace Violence 317
 *0812 - Appropriate Staffing Levels 317
 0703 - Image of and Career Opportunities for Hospital and Health-System Pharmacists 317
 0713 - Tobacco and Tobacco Products 317
 0615 - Influenza Vaccination Requirements to Advance Patient Safety and Public Health 317
 0508 - Financial Management Skills 317
 0511 - Professional Development 317
 0521 - Opposition to Creation of New Categories of Licensed Personnel 318
 0409 - Cultural Diversity Among Health Care Providers 318
 0318 - Role of Licensing, Credentialing, and Privileging in Collaborative Drug Therapy Management 318
 0201 - Staffing for Safe and Effective Patient Care 318
 0211 - Image of and Career Opportunities for Pharmacy Technicians 318
 0218 - Pharmacist Recruitment and Retention 318
 0110 - Professional Socialization 319
 0112 - Professional Development as a Retention Tool 319

*Indicates content that has been added or revised since the 2007–2008 edition.

	0006 - Pharmacist Credentialing	319
	9103 - Drug Testing.....	319
	9108 - Employee Testing.....	319
	8610 - Pharmacy Technicians.....	319
GUIDELINE:	Recruitment, Selection, and Retention of Pharmacy Personnel.....	320
REPORT:	Long-Range Vision for the Pharmacy Work Force in Hospitals and Health Systems	326
ENDORSED:	White Paper on Pharmacy Technicians	336
Practice Settings		
POSITIONS:	0709 - Principles of Managed Care.....	352
	0414 - Home Intravenous Therapy Benefit.....	352
GUIDELINES:	Minimum Standard for Home Care Pharmacies	353
	Minimum Standard for Pharmaceutical Services in Ambulatory Care.....	362
	Minimum Standard for Pharmacies in Hospitals	371
	Pharmaceutical Services in Correctional Facilities	377
	Pharmacist's Role in Home Care.....	381
Research		
POSITIONS:	0711 - Institutional Review Boards and Investigational Use of Drugs	388
	0229 - Clinical Investigations of Drugs Used in Elderly and Pediatric Patients.....	388
STATEMENT:	Pharmaceutical Research in Organized Health-Care Settings.....	389
GUIDELINES:	Clinical Drug Research	390
	Pharmaceutical Research in Organized Health-Care Settings.....	397
ASHP Therapeutic Position Statements		
	*Antithrombotic Therapy in Chronic Atrial Fibrillation.....	400
	Appropriate Use of Medications in the Treatment of Attention-Deficit/Hyperactivity Disorder in Pediatric Patients	410
	Daily Use of Aspirin for Preventing Cardiovascular Events.....	417
	Institutional Use of 0.9% Sodium Chloride Injection to Maintain Patency of Peripheral Indwelling Intermittent Infusion Devices.....	424
	Preferential Use of Metronidazole for the Treatment of <i>Clostridium difficile</i> -Associated Disease.....	427
	*Prevention and Treatment of Osteoporosis in Adults.....	431
	Safe Use of Oral Nonprescription Analgesics.....	445
	Safe Use of Pharmacotherapy for Obesity Management in Adults.....	450
	Strategies for Identifying and Preventing Pneumococcal Resistance.....	460
	Strict Glycemic Control in Patients with Diabetes.....	465
	Treatment of Hypertension.....	470
	Use of Low-Molecular-Weight Heparins for Adult Outpatient Treatment of Acute Deep-Vein Thrombosis.....	477
	Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders.....	483

ASHP Therapeutic Guidelines

Antimicrobial Prophylaxis in Surgery	498
Sedation, Analgesia, and Neuromuscular Blockade of the Critically Ill Adult: Revised Clinical Practice Guidelines for 2002	546
Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient	548
Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult	564
Index	592

*Indicates content that has been added or revised since the 2007–2008 edition.

Page Locator for Guidance Documents by Type and Title

ASHP Statements

Bar-Code-Enabled Medication Administration Technology	6
Confidentiality of Patient Health Care Information	197
Continuing Education	105
Drug Delivery Systems and Administration Devices	13
Criteria for an Intermediate Category of Drug Products	150
Hospitalist–Pharmacist Collaboration	198
Over-the-Counter Availability of Statins	153
Pharmaceutical Care	202
Pharmaceutical Research in Organized Health-Care Settings	389
Pharmacist’s Decision-making on Assisted Suicide	111
Pharmacist’s Responsibility for Distribution and Control of Drug Products	85
Pharmacist’s Role in Clinical Pharmacokinetic Monitoring	221
Pharmacist’s Role in Hospice and Palliative Care	223
Pharmacist’s Role in Infection Control	227
Pharmacist’s Role in Informatics	9
Pharmacist’s Role in Primary Care	229
Pharmacist’s Role in Substance Abuse Prevention, Education, and Assistance	232
Pharmacist’s Role in the Care of Patients with HIV Infection	236
Pharmacy and Therapeutics Committee and the Formulary System	122
Pharmacy Services to the Emergency Department	241
Principles for Including Medications and Pharmaceutical Care in Health Care Systems	156
Professionalism	114
Racial and Ethnic Disparities in Health Care	244
Reporting Medical Errors	159
Role of Health-System Pharmacists in Emergency Preparedness	249
Role of Health-System Pharmacists in Public Health	251
Roles and Responsibilities of the Pharmacy Executive	289
Standards-Based Pharmacy Practice in Hospitals and Health Systems	292
Unit Dose Drug Distribution	86
Use of Dietary Supplements	256
Use of Medications for Unlabeled Uses	125

ASHP Guidelines

Activities of Vendors’ Representatives in Organized Health Care Systems	285
Adverse Drug Reaction Monitoring and Reporting	160
Clinical Drug Research	390
Documenting Pharmaceutical Care in Patient Medical Records	205

Handling Hazardous Drugs	36
Managing Drug Product Shortages	28
Medication Cost Management Strategies for Hospitals and Health Systems	294
Medication-Use Evaluation	127
Minimum Standard for Home Care Pharmacies	353
Minimum Standard for Pharmaceutical Services in Ambulatory Care.....	362
Minimum Standard for Pharmacies in Hospitals.....	371
Outsourcing Pharmaceutical Services	309
Pharmaceutical Research in Organized Health-Care Settings.....	397
Pharmaceutical Services in Correctional Facilities	377
Pharmacist-Conducted Patient Education and Counseling	208
Pharmacists' Relationships with Industry	117
Pharmacist's Role in the Development, Implementation, and Assessment of Critical Pathways	211
Pharmacist's Role in Home Care.....	381
Pharmacist's Role in Immunization.....	261
Pharmacy and Therapeutics Committee and the Formulary System.....	130
Pharmacy-Prepared Ophthalmic Products.....	56
Preventing Medication Errors in Hospitals.....	163
Preventing Medication Errors with Antineoplastic Agents.....	172
Providing Pediatric Pharmaceutical Services in Organized Health Care Systems.....	267
Provision of Medication Information by Pharmacists.....	270
Quality Assurance for Pharmacy-Prepared Sterile Products.....	58
Recruitment, Selection, and Retention of Pharmacy Personnel	320
Safe Use of Automated Compounding Devices for the Preparation of Parenteral Nutrition Admixtures	15
Safe Use of Automated Medication Storage and Distribution Devices	20
Selecting Pharmaceutical Manufacturers and Suppliers	33
Standardized Method for Pharmaceutical Care.....	217
Surgery and Anesthesiology Pharmaceutical Services.....	273
ASHP Report	
Long-Range Vision for the Pharmacy Work Force in Hospitals and Health Systems	326
ASHP Technical Assistance Bulletins	
Compounding Nonsterile Products in Pharmacies.....	77
Hospital Drug Distribution and Control	87
Repackaging Oral Solids and Liquids in Single Unit and Unit Dose Packages.....	96
Single Unit and Unit Dose Packages of Drugs.....	98

Acknowledgments

A SHP gratefully acknowledges the following organizations and individuals for drafting and reviewing* the new and revised guidance documents in this edition.

*ASHP–SHM Joint Statement on
Hospitalist–Pharmacist Collaboration*

Drafters: Daniel J. Cobaugh, Pharm.D., FAACT,
DABAT
Alpesh Amin, M.D., M.B.A., FACP
Thomas C. Bookwalter, Pharm.D.
Mark Williams, M.D., FACP
Patricia Grunwald, Pharm.D.
Cynthia LaCivita, Pharm.D.
Bruce Hawkins, B.A., B.S.

Reviewers: American Academy of Physician Assistants
(AAPA)
American Nurses Association (ANA)
American Society of Consultant Pharmacists
(ASCP)

Nicole M. Allcock, Pharm.D., BCPS
Philip Anderson, Pharm.D., FASHP
Linda C. Anecchini, M.S., FASHP
John A. Armitstead, M.S., FASHP
Carol Bickford, Ph.D., RN-BC (ANA)
Michael L. Brandt, B.S., Pharm.D.
John Bridges, Pharm.D.
Tim R. Brown, Pharm.D.
Gail M. Burniske, Pharm.D., BCPS
Margaret Chrymko, Pharm.D., FASHP
Steve Crane (AAPA)
Karren Crowson, M.B.A.
Lourdes M. Cuellar, M.S., FASHP
Michele Danish, Pharm.D.
Neil M. Davis, M.S., Pharm.D., FASHP
Jean B. Douglas, Pharm.D.
Jillian James Foster, Pharm.D.
Georgia W. Fox, Pharm.D.
Nicole Gara (AAPA)
Kathleen M. Gura, Pharm.D., BCNSP,
FASHP
Stuart T. Haines, Pharm.D., FCCP, FASHP
Tom Hall, Pharm.D.
John Hertig, Pharm.D.
Philip E. Johnson, Pharm.D., M.S., FASHP
Thomas J. Johnson, Pharm.D., BCPS
Michael Kelly, M.S., Pharm.D., FASHP
Patricia Kienle, B.S.Pharm., M.P.A., FASHP
Kathrin C. Kucharski, Pharm.D., BCPS
Sharon Kulesz (AAPA)
Timothy R. Lanese, M.B.A., FASHP,
FACHE
Bob McNellis, M.P.H., PA (AAPA)
Joe Miller, M.D. (SHM)

Rima Mohammad, Pharm.D., BCPS
Lynette R. Moser, Pharm.D.
Joe E. Ness, M.H.A.
Scott Oxenhandler, M.D.
Charles D. Ponte, Pharm.D., BC-ADM,
BCPS, CDE, FAPhA, FASHP, FCCP
James A. Ponto, M.S., BCNP, FASHP
Michael D. Sanborn, M.S.
Phil Saucedo, M.B.A.
Kenneth H. Schell, Pharm.D., FASHP,
FCSHP
Edward C. Seidl, Pharm.D.
Michele F. Shepherd, Pharm.D., M.S.,
BCPS, FASHP
Jonalan Smith, Pharm.D. (ASCP)
Kelly M. Smith, Pharm.D.
Miriam A. Mobley Smith, Pharm.D.
Edward Stemley, M.S., Pharm.D.
Joe Strain, Pharm.D.
James A. Trovato, Pharm.D., M.B.A., BCOP
Jennifer Tryon, Pharm.D., M.S.
Laura Wachter, Pharm.D.
William E. Wade, Pharm.D., FASHP, FCCP
Paul C. Walker, Pharm.D.
Larry Wellikson, M.D. (SHM)
Karl G. Williams, J.D., M.S.
John L. Woon, Pharm.D., FASHP

*ASHP Statement on Pharmacy Services
to the Emergency Department*

Drafters: Roshanak Aazami, Pharm.D.
Elizabeth A. Clements, Pharm.D.
Daniel J. Cobaugh, Pharm.D., FACCT,
DABAT
Frank P. Paloucek, Pharm.D.

Reviewers: American Academy of Emergency Medicine
(AAEM)
American Academy of Pediatrics,
Committee on Pediatric Emergency
Medicine and Section on Emergency
Medicine (AAP)
American College of Emergency Physicians
(ACEP)
American Nurses Association (ANA)
American Organization of Nurse Executives
(AONE)
American Society for Clinical Pharmacology
and Therapeutics (ASCPT)

*Review does not imply endorsement.

ASHP Section of Clinical Specialists and
Scientists Section Advisory Group on
Emergency Care (SCSS SAG)
Emergency Nurses Association (ENA)
National Association of Emergency Medical
Technicians (NAEMT)
Society of Critical Care Medicine (SCCM)
The Joint Commission (TJC)

Jennifer Albrich, Pharm.D., BCPS
Teri L. Bair, J.D.
Amanda M. Ball, Pharm.D.
Sandra L. Bardas, ED
Joseph Barone, Pharm.D., FCCP
Carol Bickford, Ph.D., RN-BC (ANA)
Fredrick C. Blum, MD, FACEP, FAAP
(ACEP)
Nancy Bonalumi, RN, M.S., CEN (ENA)
Helen M. Calmes, Pharm.D., M.B.A.
Kenneth Daee
George Delgado, Jr., Pharm.D. (SCSS SAG)
Charles G. Durbin, Jr., M.D., FCCM
(SCCM)
Heather Eyrich, Pharm.D.
Brian D. Faley, Pharm.D.
Wendy J. Friedig, Pharm.D., M.B.A.
Matthew J. Geraci, Pharm.D., EOD
Karen Gurwitch, Pharm.D. (SCSS SAG)
Daniel P. Hays, Pharm.D., BCPS (SCSS
SAG)
Mary Hess, Pharm.D.
Umbreen Idrees, Pharm.D., BCPS (SCSS
SAG)
Stanley S. Kent, M.S.
Todd D. Lemke, Pharm.D., C.D.E. (SCSS
SAG)
Gary R. Matzke, Pharm.D., FCP, FCCP
Julie R. McCoy, Pharm.D.
Mary T. Meadows, RN, M.S., M.B.A.
(AONE)
Paula J. Mialon, Pharm.D., J.D.
Leila R. Mohassel, Pharm.D.
Vincent N. Mosesso, Jr., M.D., FACEP
(NAEMT)
Robert S. Oakley, M.S.
Edward C. Rainville, Pharm.M.S.
Katharine A. Reisbig, Pharm.D., BCPS
James R. Rinehart, M.S.
Michael Roberts, M.S.
Lou E. Romig, M.D., FAAP, FACEP
(NAEMT)
Maria I. Rudis, Pharm.D., FCCM (SCSS
SAG)
Kevin O. Rynn, Pharm.D., FCCP, DABAT
Tom Scaletta, M.D., FAAEM (AAEM)
Paul Setlak, Pharm.D.
Greene Shepherd, Pharm.D., DABAT
Suzanne Stone-Griffith, M.S.N., CNAA
Richard Thomas, Pharm.D., DABAT
Keith B. Thomasset, Pharm.D., BCPS
James A. Trovato, Pharm.D., M.B.A.,
BCOP (SCSS SAG)

Alexander A. Vinks, Pharm.D., Ph.D., FCP
(ASCPT)
Brian K. Werner, MPT
Brenda K. White, RN, B.S.N., M.H.A., MJ
(TJC)
Norman Wiginton, M.S.M.
Jimmy Williams, B.S.
Peter J. Zed, Pharm.D., FCSHP

*ASHP Statement on the P&T Committee
and the Formulary System*

Drafters: Linda S. Tyler, Pharm.D., FASHP
Mirta Millares, Pharm.D., FCSHP, FASHP
Andrew L. Wilson, Pharm.D., FASHP
Lee C. Vermeulen, Jr., B.S.Pharm., M.S.
J. Russell (Rusty) May, Pharm.D., FASHP
Michael A. Valentino, R.Ph. MHSA
Sabrina W. Cole, Pharm.D., BCPS

Reviewers: Academy of Managed Care Pharmacy
(AMCP)
American Nurses Association (ANA)
American Society for Clinical Pharmacology
and Therapeutics (ASCPT)
American Society of Consultant Pharmacists
(ASCP)
Institute for Safe Medication Practices
(ISMP)
Pharmacy Compounding Accreditation
Board (PCAB)

Daniel T. Abazia, Pharm.D.
Philip Anderson, Pharm.D., FASHP
Lilian M. Azzopardi, B.Pharm.(Hons),
M.Phil., Ph.D.
Kenneth R. Baker, J.D. (PCAB)
James L. Besier, Ph.D., FASHP
J. Lyle Bootman, Ph.D., Sc.D.
David G. Bowyer, B.S.
Maureen Brady, Pharm.D.
Margaret Chrymko, Pharm.D., FASHP
Joseph W. Cranston, Ph.D.
Steven Dzierba, M.S., FASHP
Michael Gaunt, Pharm.D. (ISMP)
Pamela C. Hagan, M.S.N., RN (ANA)
Raymond W. Hammond, Pharm.D., BCPS,
FCCP
Eric T. Hola, M.S.
Patricia Kienle, B.S.Pharm., M.P.A., FASHP
Katharine Kiser, Pharm.D.
Thomas L. Kurt, M.D., M.P.H., FACPM,
FACMMT, FAACT, FCP, FACE (ASCPT)
Timothy R. Lanese, M.B.A., FASHP,
FACHE
Rosario (Russ) J. Lazzaro, M.S.
Melvin E. Liter, M.S., Pharm.D.
Patrick M. Malone, Pharm.D., FASHP
Candis M. Morello, Pharm.D., CDE, FCSHP
Richard O'Brocta, Pharm.D., BCPS
Folakemi T. Odedina, Ph.D.
James A. Ponto, M.S., BCNP, FASHP

Curt W. Quap, M.S.
 Mike Rouse, B.Pharm.(Hons), M.P.S.
 Marissa Schlaifer, M.S. (AMCP)
 Shelley Hoppe Schliesser, Pharm.D.
 Michele F. Shepherd, Pharm.D., M.S.,
 BCPS, FASHP
 Jonalan Smith, Pharm.D. (ASCP)
 Allen J. Vaida, Pharm.D., FASHP (ISMP)
 William E. Wade, Pharm.D., FASHP, FCCP
 Tom W. Woller, M.S., FASHP
 John L. Woon, Pharm.D., FASHP

*ASHP Statement on Standards-based Pharmacy Practice
 in Hospitals and Health Systems*

Drafters: Scott Mark, Pharm.D., M.S., M.Ed., CHE,
 FASHP, FABC

Reviewers: American Association of Critical Care
 Nurses (AACN)
 American Society of Consultant Pharmacists
 (ASCP)
 Accreditation Council for Pharmacy
 Education (ACPE)
 Institute for Safe Medication Practices
 (ISMP)
 South Carolina Society of Health-System
 Pharmacists (SCSHP)

R. Paul Baumgartner, B.Pharm., D.Sc.,
 FASHP
 Linda Bell, RN, M.S.N. (AACN)
 Helen M. Calmes, Pharm.D., M.B.A.
 Thomas R. Clark (ASCP)
 Toby Clark, M.Sc., FASHP
 Kevin J. Colgan, M.A., FASHP
 Jennifer Cimoch, Pharm.D.
 Mandy Davis, Pharm.D.
 Jean B. Douglas, Pharm.D.
 Martha Fankhauser, M.S.Pharm.
 Christopher Fortier, Pharm.D.
 Kelli Gibson, Pharm.D.
 Tom Hall, Pharm.D.
 Leslie Hamilton, Pharm.D.
 Erin Hendrick, Pharm.D.
 Amy Hyduk, Pharm.D.
 Philip E. Johnson, Pharm.D., M.S., FASHP
 Patricia Kienle, B.S.Pharm., M.P.A., FASHP
 Justin Konkol, Pharm.D.
 Rosario (Russ) J. Lazzaro, M.S.
 Jeff Little, Pharm.D.
 Joel Marrs, Pharm.D.
 Jay M. Mirtallo, M.S., BCNSP, FASHP
 Natasha Nicol, Pharm.D. (SCSHP)
 Marjorie Shaw Phillips, M.S., FASHP
 Brandon Ordway, Pharm.D.
 Charles D. Ponte, Pharm.D., BC-ADM,
 BCPS, CDE, FAPhA, FASHP, FCCP
 James A. Ponto, M.S., BCNP, FASHP
 Darryl S. Rich, Pharm.D., M.B.A., FASHP
 Michael J. Rouse, B.Pharm. (Hons), M.P.S.
 (ACPE)

Richard I. Sakai, Pharm.D., FASHP, FCSHP
 Daryl Schiller, Pharm.D., M.S.
 Stephanie Thune, Pharm.D.
 Dennis Tribble, Pharm.D.
 Allen J. Vaida, Pharm.D., FASHP (ISMP)

*ASHP Statement on the Roles and Responsibilities
 of the Pharmacy Executive*

Drafters: John E. Clark, Pharm.D.
 Rosario (Russ) J. Lazzaro, M.S.
 Douglas A. Miller, Pharm.D.

Reviewers: Academy of Managed Care Pharmacy
 (AMCP)
 American Association of Critical Care
 Nurses (AACN)
 American Geriatric Society (AGS)
 American Nurses Association (ANA)

David N. Adelman, M.S.
 Stephen J. Allen, M.S., FASHP
 Michael Anderson, Pharm.D. (AGS)
 John A. Armitstead, M.S., FASHP
 J. G. Barbaccia, Pharm.D., FASHP
 Linda Bell, RN, M.S.N. (AACN)
 Donna D. Bellamy, Pharm.D.
 James L. Besier, Ph.D., FASHP
 Carol Bickford, Ph.D., RN-BC (ANA)
 Wayne S. Bohenek, Pharm.D., M.S., FASHP
 Sally Brooks, M.D., AGSF (AGS)
 Mark N. Brueckl, M.B.A. (AMCP)
 Kathryn K. Bucci, Pharm.D., FASHP,
 FAHM, BCPS
 Helen M. Calmes, Pharm.D., M.B.A.
 Marvin A. Chamberlain, M.S., FASHP
 Toby Clark, M.Sc., FASHP
 Kevin J. Colgan, M.A., FASHP
 Karren Crowson, M.B.A.
 Terri Davidson, Pharm.D., BCOP, FASHP,
 FCCP
 Robert DeChristoforo, M.S., FASHP
 Paul Driver, Pharm.D., BCPS
 Steven Dzierba, M.S., FASHP
 Jennifer M. Edwards, Pharm.D.
 Brent R. Ekins, Pharm.D., DABAT, FAACT,
 FASHP
 Andre Emont, M.S.
 Nora B. Flint, Pharm.D., BCPS
 Brent I. Fox, Pharm.D.
 Lisa M. Gersema, Pharm.D., BCPS
 Shelly Gray, Pharm.D. (AGS)
 Bill Greene, Pharm.D., BCPS, FASHP
 Kathleen M. Gura, Pharm.D., BCNSP,
 FASHP
 James M. Hoffman, Pharm.D., M.S., BCPS
 Teresa J. Hudson, Pharm.D., BCPP, FASHP
 Edward M. Jai, Pharm.D.
 Philip E. Johnson, Pharm.D., M.S., FASHP
 Tom Kaye, M.B.A.
 Stanley S. Kent, M.S., FASHP
 Patricia Kienle, B.S.Pharm., M.P.A., FASHP

Bonnie E. Kirschenbaum, M.S., FASHP
 Karen E. Koch, Pharm.D., M.S.H.A.
 George R. (Ron) Kolar, B.S.Pharm., M.S.,
 FASHP
 Timothy R. Lanese, M.B.A., FASHP,
 FACHE
 Rosario (Russ) J. Lazzaro, M.S.
 Ray R. Maddox, Pharm.D.
 Henri R. Manasse, Jr., Ph.D., Sc.D.
 Mary McGuiggan, Pharm.D (AGS)
 Joseph J. Medicis, Pharm.D., BCPS, FASHP
 Robert F. Miller, M.S.
 Anthony P. Morreale, Pharm.D., M.B.A.,
 BCPS, FASHP
 Paul J. Mosko, M.S., FASHP
 Peggy Odegard, Pharm.D (AGS)
 Rebecca M. Patton, M.S.N., RN, CNOR
 (ANA)
 John Poikonen, Pharm.D.
 Charles D. Ponte, Pharm.D., BC-ADM,
 BCPS, CDE, FAPhA, FASHP, FCCP
 James A. Ponto, M.S., BCNP, FASHP
 Michael F. Powell, M.S., FASHP
 Steve Rough, M.S.
 Randall Rowen, Pharm.D. (AGS)
 Wayne L. Russell, Pharm.D., FASHP
 Mark H. Siska, B.S.Pharm., M.B.A./T.M.
 Cathy Stamer, Pharm.D (AGS)
 Richard Stefanacci, DO, MGH (AGS)
 James G. Stevenson, Pharm.D., FASHP
 Linda J. Stierle, M.S.N., RN, CNA, BC
 (ANA)
 Eric Tangelos, M.D. (AGS)
 Lance Tillett, M.P.H.
 Dennis Tribble, Pharm.D.
 Shawn M. Ulreich, RN, M.S.N.
 Paul C. Walker, Pharm.D.
 Jody Jacobson Wedret, FASHP, FCSHP
 Randy Ziss, Pharm.D., BCPS, FASHP

*ASHP Statement on Criteria for
 an Intermediate Class of Drugs*

Reviewers: James W. Atkins
 R. Paul Baumgartner, B.Pharm., D.Sc.,
 FASHP
 Donna D. Bellamy, Pharm.D.
 Rosemary R. Berardi, Pharm.D., FCCP,
 FASHP, FAPhA
 Keith Boesen, Pharm.D., CSPI
 Susan Teil Boyer, M.S., FASHP
 Michael R. Cohen, M.S., Sc.D.
 Ernest Dole, Pharm.D., PhC, BCPS, CDE,
 FASHP
 Jean B. Douglas, Pharm.D.
 Steven Dzierba, M.S., FASHP
 Martha Fankhauser, M.S.Pharm.
 Erin R. Fox, Pharm.D.
 Jeffery A. Goad, Pharm.D., M.P.H., FCPhA,
 FCSHP
 John Grabenstein, Ph.D.
 David Hartzell, Pharm.D., BCPS, CACP

Edward M. Jai, Pharm.D.
 Michael Kelly, M.S., Pharm.D., FASHP
 Patricia Kienle, B.S.Pharm., M.P.A., FASHP
 Timothy Lynch, Pharm.D., M.S.M.
 James A. Ponto, M.S., BCNP, FASHP
 Richard I. Sakai, Pharm.D., FASHP, FCSHP
 Kenneth H. Schell, Pharm.D., FASHP,
 FCSHP
 Peg Panella-Spangler, M.S., RD, FASHP
 Susan M. Stein, M.S.
 Jody Jacobson Wedret, FASHP, FCSHP
 Randy Ziss, Pharm.D., BCPS, FASHP

*ASHP Statement on Bar-Code-Enabled
 Medication Administration Technology*

Drafters: Arash T. Dabestani, Pharm.D., M.H.A.,
 FABC
 Alicia B. Perry, Pharm.D.

Reviewers: American Association of Critical Care
 Nurses (AACN)
 Academy of Managed Care Pharmacy
 (AMCP)
 American Nurses Association (ANA)
 Healthcare Information and Management
 Systems Society (HIMSS)
 Institute for Safe Medication Practices
 (ISMP)
 National Council for Prescription Drug
 Programs (NCPDP)
 South Carolina Society of Health-System
 Pharmacists (SCSHP)
 South Dakota Society of Health-System
 Pharmacists (SDSHP)

Martin H. Abramson, M.S., FASHP
 David B. Archer, B.S.Pharm.
 Dean A. Bennett, B.S.Pharm.
 Richard P. Bernardi, M.H.A.
 Anne M. Bobb, B.S.Pharm.
 Mark N. Brueckl, B.S.Pharm., M.B.A.
 (AMCP)
 David Chen, B.S.Pharm., M.B.A.
 William W. Churchill, M.S.
 Frederick E. Coleman III, M.B.A., FASHP
 Jan Denecker
 Edward Dzwil, B.S. Engr., M.B.A., CPP
 Jeanne R. Ezell, M.S.
 David C. Gammon, B.S.Pharm.
 Bernard J. (Joe) Guglielmo, Jr., Pharm.D.
 Christopher G. Harris, Pharm.D.
 Jane S. Henry, M.B.A., FASHP
 Eric T. Hola, M.S.
 Edward M. Jai, Pharm.D.
 Tom Kaye, M.B.A., FASHP
 Bonnie E. Kirschenbaum, M.S., FASHP
 Richard Kriozere
 Randy L. Kuiper, Pharm.D.
 Jason Kulaga, RN, B.S.N.
 Geoffrey C. Lawton, M.B.A., M.H.A.
 Matthew Levanda, B.S.Pharm., M.B.A.

Stuart Levine, Pharm.D. (ISMP)
 Hetty A. Lima, B.S.Pharm., FASHP
 Jeff Little, Pharm.D.
 William A. Lockwood, Jr.
 Michael McGregory, Pharm.D., BCPS
 Barbara Medling, RN, B.S.N., CNOR,
 RN-BC
 Gerald E. Meyer, Pharm.D., M.B.A.,
 FASHP
 John F. Mitchell, Pharm.D., FASHP
 Anne E. Morstad, Pharm.D., BCPP
 (SDSHP)
 Bob Moscoe, Pharm.D.
 Charles E. Myers, M.S., M.B.A.
 Mark Neuenschwander, B.Sc.
 Natasha Nicol, Pharm.D. (SCSHP)
 Agatha Nolen, M.S., D.Ph., FASHP
 Rebecca M. Patton, M.S.N., RN, CNOR
 (ANA)
 John C. Poikonen, Pharm.D.
 Charles D. Ponte, Pharm.D., BC-ADM,
 BCPS, CDE, FAPhA, FASHP, FCCP
 Carol Rollins, Pharm.D., BCNSP
 Steve Rough, M.S.
 Cathy L. Sasser, B.S.Pharm.
 Paul M. Seelinger, B.S.Pharm.
 Joyce Sensmeier, M.S., RN-BC, CPHIMS,
 FHIMSS (HIMSS)
 Gregory K. Shaeffer, M.B.A., FASHP
 Michael D. Schlesselman, Pharm.D.,
 FASHP
 Todd Semla, M.S., Pharm.D., BCPS, FCCP,
 AGSF
 Pamela Shellner, RN, M.A. (AACN)
 Mohammad Siddiqui, Pharm.D.
 Almeda D. Simpson, B.S.Pharm., FASCP
 Peter Spiro, M.D., FCCP
 Lee Ann Stember, B.S. (NCPDP)
 Linda J. Stierle, M.S.N., RN, CNA, BC
 (ANA)
 Dennis C. Taylor, M.B.A.
 Gayle E. Thomas, Pharm.D.
 Dennis Tribble, Pharm.D.
 Robbie G. Trussell, FASHP, FHIMSS
 Pete A. Van Aarle, B.S.Pharm.
 Rayburn V. Vrabell, Pharm.D.
 Jody Jacobson Wedret, FASHP, FCSHP
 Barbara White, CPhT

*ASHP Guidelines on the P&T Committee
 and the Formulary System*

Authors: Linda S. Tyler, Pharm.D., FASHP
 Mirta Millares, Pharm.D., FCSHP, FASHP
 Andrew L. Wilson, Pharm.D., FASHP
 Lee C. Vermeulen, Jr., B.S.Pharm., M.S.
 J. Russell (Rusty) May, Pharm.D., FASHP
 Michael A. Valentino, R.Ph., MHSA
 Sabrina W. Cole, Pharm.D., BCPS

Reviewers: American Society for Clinical Pharmacology
 and Therapeutics (ASCPT)

Academy of Managed Care Pharmacy
 (AMCP)
 American Nurses Association (ANA)
 American Geriatrics Society (AGS)

Philip Anderson, Pharm.D., FASHP
 Lilian M. Azzopardi, B.Pharm., M.Phil.,
 Ph.D.
 Joseph S. Bertino Jr., Pharm.D.
 Thomas C. Bookwalter, Pharm.D.
 Maureen Brady, Pharm.D.
 Kathy A. Chase, Pharm.D.
 Margaret Chrymko, Pharm.D., FASHP
 Shelby L. Corman, Pharm.D., BCPS
 Joseph W. Cranston, Ph.D.
 Steven Dzierba, B.S.Pharm., M.S., FASHP
 Raulo S. Frear, Pharm.D., M.S.
 Pamela C. Hagan, M.S.N, RN
 Raymond W. Hammond, Pharm.D., M.S.,
 BCPS, FCCP
 Patricia Kienle, B.S.Pharm., M.P.A., FASHP
 Donald T. Kishi, Pharm.D., FCSHP
 George R. (Ron) Kolar, B.S.Pharm., M.S.,
 FASHP
 Thomas L. Kurt, M.D., M.P.H., FACPM,
 FACMMT, FAACT, FCP, FACE
 Timothy R. Lanese, B.S.Pharm., M.B.A.,
 FASHP, FACHE
 Rosario (Russ) J. Lazzaro, M.S.
 Michael J. Magee, M.S., B.S.Pharm.,
 FASHP
 Patrick M. Malone, Pharm.D., FASHP
 Folakemi T. Odedina, Ph.D.
 Charles D. Ponte, Pharm.D., BC-ADM,
 BCPS, CDE, FAPhA, FASHP, FCCP
 James A. Ponto, M.S., BCNP, FASHP
 Curt W. Quap, M.S., B.S.Pharm.
 Karen L. Rascati, B.S.Pharm., M.S., Ph.D.,
 FAPhA
 Marissa Schlaifer, M.S. (AMCP)
 Shelley Hoppe Schliesser, Pharm.D.
 Todd Semla, M.S., Pharm.D., BCPS, FCCP,
 AGSF
 Bonnie Senst, M.S., B.S.Pharm., FASHP
 Michele F. Shepherd, Pharm.D., M.S.,
 BCPS, FASHP
 Jonalan Smith, Pharm.D.
 Janice L. Stumpf, Pharm.D.
 John P. Swenson, B.S.Pharm., M.S., FASHP
 Paul C. Walker, Pharm.D.
 Tom W. Woller, M.S., FASHP
 John L. Woon, Pharm.D., FASHP

*ASHP Guidelines on Medication Cost Management
 Strategies for Hospitals and Health Systems*

Authors: Michael Rubino, M.S., FASHP
 James M. Hoffman, Pharm.D., M.S., BCPS
 Larry J. Koesterer, M.B.A.
 Robert G. Swendrzynski, M.S.

Reviewers: John A. Armitstead, M.S., FASHP

William W. Churchill, M.S.
 Glen T. Schumock, Pharm.D., M.B.A.,
 FCCP
 Nilay D. Shah, Ph.D.
 Katie J. Suda, Pharm.D.
 Lee C. Vermeulen, Jr., B.S.Pharm., M.S.

*ASHP Therapeutic Position Statement on the Prevention
 and Treatment of Osteoporosis in Adults*

Authors: Eric J. MacLaughlin, Pharm.D., BCPS
 Cynthia L. Raehl, Pharm.D., FASHP, FCCP

Reviewers: Academy of Managed Care Pharmacy
 American College of Clinical Pharmacy
 Women's Health PRN Group
 National Consumers League
 NPS Pharmaceuticals

Nick P. Beckey, Pharm.D., BCPS
 Andrea S. Franks, Pharm.D., BCPS
 Jill Heitzman, PT, DPT, GCS, CWS
 David L. Lourwood, Pharm.D., BCPS,
 FCCP
 Cam Nguyen, Pharm.D.
 Marjorie Shaw Phillips, M.S., FASHP
 Jane Tennis, M.B.A., B.S.Pharm.

*ASHP Therapeutic Position Statement on Antithrombotic
 Therapy in Chronic Atrial Fibrillation*

Author: Edith A. Nutescu, Pharm.D., FCCP

Reviewers: Jerry L. Bauman, Pharm.D., FCCP, FACC
 Christopher M. Dezii, RN, M.B.A., CPHQ
 Robert J. DiDomenico, Pharm.D.
 Todd R. Marcy, Pharm.D., BCPS, CDE
 Mary Pubentz, Pharm.D., CACP
 Paul C. Walker, Pharm.D.
 Ann K. Wittkowsky, Pharm.D., CACP,
 FASHP, FCCP

*ASHP Therapeutic Position Statement
 on the Cessation of Tobacco Use*

Authors: Karen Suchanek Hudmon, Dr.P.H., M.S.
 Robin L. Corelli, Pharm.D.

Reviewers: American Nurses Association (ANA)

John R. Hughes, M.D.
 Connie C. Revell, M.A.
 Mary H. Zimmerman, BCPS, CACP
 Thomas P. Houston, M.D., FAAFP, FACPM
 Candice Garwood, Pharm.D., BCPS
 Karen Gunning, Pharm.D., BCPS
 Carol Southard, R.N., M.S.N. (ANA)
 Alan J. Zillich, Pharm.D.
 Laura B. Hanson, Pharm.D.
 Daniel A. Hussar, Ph.D.